Apellis Pharmaceuticals, Inc. (APLS) Q3 2018 Earnings Results

Apellis Pharmaceutical Misses on EPS, Stock Up 3.39%

The earnings report indicates that Apellis Pharmaceutical is still in a development phase, as reflected by the negative EPS. Despite this, the stock rose by 3.39%, likely due to positive sentiment around their ongoing projects and management's optimistic outlook. Investors may be encouraged by the potential for future growth as the company continues to work on its pipeline.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.64	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Cautiously Optimistic

Overall, management conveyed a sense of cautious optimism about the company's future prospects. They emphasized their commitment to advancing their clinical programs.

Management highlighted ongoing developments in their pipeline.

They expressed confidence in future product launches despite current losses.

Apellis Pharmaceutical Misses on EPS, Stock Up 3.39%

Key numbers

Management commentary

Apellis Pharmaceuticals, Inc.

More earnings this week

Apellis Pharmaceutical Misses on EPS, Stock Up 3.39%

Key numbers

Management commentary